The impact of decentralized trials
And On Track
During the COVID-19 pandemic, the need for decentralized trials has grown exponentially in tandem with the development of new clinical technologies. These new options for sites, patients and study teams will remain an important attribute of clinical trials beyond the pandemic.
With this in mind, PPD’s recent survey illustrates the significance of hybrid and decentralized trials during the pandemic and beyond.
Within the survey report, you’ll learn how leading biopharma and biotech organizations responded to questions such as:
- How has the current Covid-19 crisis impacted your ongoing clinical trials?
- What technologies are being implemented by your organization to mitigate the impact of Covid-19 on your clinical trials?
- With decentralized trials/strategies, have expectations been met, unmet, or exceeded?
- What’s the primary benefit your organization has seen from its decentralized trials?